Evaluation of (188)Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model (original) (raw)

Abstract

sparkles

AI

This study evaluates the potential of (188)Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in treating glioblastoma multiforme (GBM) using an orthotopic glioma-bearing rat model. The research emphasizes the need for effective treatment options, considering the limited survival rates associated with current therapies. The findings suggest that the 188Re-liposome significantly prolongs survival in treated rats compared to controls, indicating its promise as a therapeutic strategy in improving outcomes for GBM patients.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (43)

  1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2005-2009. Neuro Oncol. 2012;14 Suppl 5:v1-v49.
  2. Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspec- tives. J Proteomics. 2010;73(10):1823-1838.
  3. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17(12):4119-4124.
  4. Perlstein B, Finniss SA, Miller C, et al. TRAIL conjugated to nanopar- ticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol. 2013;15(1):29-40.
  5. Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M. Cur- rent therapeutic paradigms in glioblastoma. Rev Recent Clin Trials. 2010;5(1):14-27.
  6. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193-199.
  7. Dash A, Knapp FF, Pillai MR. Targeted radionuclide therapy -an overview. Curr Radiopharm. 2013;6(3):152-180.
  8. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-782.
  9. Vanpouille-Box C, Lacoeuille F, Belloche C, et al. Tumor eradica- tion in rat glioma and bypass of immunosuppressive barriers using internal radiation with Re-188-lipid nanocapsules. Biomaterials. 2011;32(28):6781-6790.
  10. Phillips WT, Goins B, Bao A, et al. Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma. Neuro Oncol. 2012;14(4):416-425.
  11. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91(6):2076-2080.
  12. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials. 2009;30(12):2302-2318.
  13. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg. 1999;90(2): 315-320.
  14. Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C, Sampson JH. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus. 2006;20(4):E12.
  15. Chen LC, Chang CH, Yu CY, et al. Biodistribution, pharmacokinetics and imaging of Re-188-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol. 2007;34(4):415-423.
  16. Chen LC, Chang CH, Yu CY, et al. Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol. 2008;35(8):883-893.
  17. Chang YJ, Chang CH, Yu CY, et al. Therapeutic efficacy and microSPECT/CT imaging of (188)Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol. 2010;37(1):95-104.
  18. Tsai CC, Chang CH, Chen LC, et al. Biodistribution and pharmacoki- netics of Re-188-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. Int J Nanomedicine. 2011;6:2607-2619.
  19. Chang YJ, Hsu CW, Chang CH, Lan KL, Ting G, Lee TW. Therapeutic efficacy of Re-188-liposome in a C26 murine colon carcinoma solid tumor model. Invest New Drug. 2013;31(4):801-811.
  20. Chang CH, Liu SY, Lee TW. Pharmacokinetics of BMEDA after intrave- nous administration in beagle dogs. Molecules. 2014;19(1):538-549.
  21. Huang FY, Lee TW, Kao CH, et al. Imaging, autoradiography, and biodistribution of (188)Re-labeled PEGylated nanoliposome in orthotopic glioma bearing rat model. Cancer Biother Radiopharm. 2011;26(6):717-725.
  22. Phillips WT, Bao A, Brenner AJ, Goins BA. Image-guided interven- tional therapy for cancer with radiotherapeutic nanoparticles. Adv Drug Deliver Rev. 2014;76:39-59.
  23. Barth RF, Kaur B. Rat brain tumor models in experimental neuro- oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol. 2009;94(3):299-312.
  24. Chow TH, Lin YY, Hwang JJ, et al. Diagnostic and therapeutic evaluation of In-111-vinorelbine-liposomes in a human colorec- tal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol. 2008;35(5):623-634.
  25. Mathieu D, Lecomte R, Tsanaclis AM, Larouche A, Fortin D. Stan- dardization and detailed characterization of the syngeneic Fischer/F98 glioma model. Can J Neurol Sci. 2007;34(3):296-306.
  26. Chen LC, Wu YH, Liu IH, et al. Pharmacokinetics, dosimetry and comparative efficacy of Re-188-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nucl Med Biol. 2012;39(1):35-43.
  27. Bryant MJ, Chuah TL, Luff J, Lavin MF, Walker DG. A novel rat model for glioblastoma multiforme using a bioluminescent F98 cell line. J Clin Neurosci. 2008;15(5):545-551.
  28. Huang FY, Chen WJ, Lee WY, Lo ST, Lee TW, Lo JM. In vitro and in vivo evaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery. Int J Mol Sci. 2013;14(2):2862-2874.
  29. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234(3):466-468.
  30. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. Re-186-liposome labeling using Re-186-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med. 2003;44(12):1992-1999.
  31. Reilly RM, Chen P, Wang J, Scollard D, Cameron R, Vallis KA. Pre- clinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of In-111-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med. 2006;47(6):1023-1031.
  32. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second- generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023-1027.
  33. Chang CH, Stabin MG, Chang YJ, et al. Comparative dosimetric evalua- tion of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy. Cancer Biother Radiopharm. 2008;23(6):749-758.
  34. Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Perme- ability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8(4):555-567.
  35. MacKay JA, Deen DF, Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diam- eter, and presence of steric coating. Brain Res. 2005;1035(2):139-153.
  36. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607-4612.
  37. Liu CM, Chang CH, Chang YJ, et al. Preliminary evaluation of acute toxicity of Re-188-BMEDA-liposome in rats. J Appl Toxicol. 2010;30(7):680-687.
  38. Chi-Mou L, Chia-Che T, Chia-Yu Y, et al. Extended acute toxicity study of Re-188-liposome in Rats. J Appl Toxicol. 2013;33(9):886-893.
  39. Towner RA, Gillespie DL, Schwager A, et al. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007. Neuro Oncol. 2013;15(3):330-340.
  40. Xi GF, Rajaram V, Mania-Farnell B, et al. Efficacy of vincristine administered via convection-enhanced delivery in a rodent brainstem tumor model documented by bioluminescence imaging. Child Nerv Syst. 2012;28(4):565-574.
  41. Barendsen GW. Dose-survival curves of human cells in tissue culture irradiated with alpha-, beta-, 20-Kv X-and 200-Kv X-radiation. Nature. 1962;193:1153-1155.
  42. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomedi- cine. 2008;3(2):181-199.
  43. Hsu WH, Liu SY, Chang YJ, Chang CH, Ting G, Lee TW. The PEGy- lated liposomal doxorubicin improves the delivery and therapeutic efficiency of (188)Re-Liposome by modulating phagocytosis in C26 murine colon carcinoma tumor model. Nucl Med Biol. 2014;41(9): 765-771.